Rigel Pharmaceuticals announced the completion of the transfer to Rigel of the New Drug Application for GAVRETO for the treatment of adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by a U.S. FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. GAVRETO will be commercially available from Rigel in the U.S. by prescription beginning June 27, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals highlights new data in three poster presentations at ASCO
- Rigel Pharmaceuticals’ Strategic Resolutions at 2024 Annual Meeting
- Rigel Pharmaceuticals announces presentations at upcoming ASCO
- Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
- Rigel Pharmaceuticals reports Q1 EPS (5c), consensus (3c)